OBJECTIVE: Large health care utilization databases are frequently used in variety of
settings to study the use and outcomes of therapeutics. Their size allows the study of …

Background The successful diffusion of new drugs is crucial for both pharmaceutical
companies and patients—and of wider stakeholder concern, including for the funding of …

Maximising the adoption of evidence‐based practice has been argued to be a major factor
in determining healthcare outcomes. However, there are gaps between evidence‐based …

Background: High-quality diabetes care is evidence-based, timely, and equitable. Sodium-
glucose cotransporter-2 inhibitors (SGLT2i) are the most recently approved class of glucose …

Background Drug companies rely on their marketing activities to influence physicians.
Previous studies showed that pharmaceutical companies succeeded to manage physicians …

Background: Inappropriate use of antibiotics promotes antibiotic resistance. Little is known
about physician characteristics that may be associated with inappropriate antibiotic …

In 2016, Batalden et al proposed a coproduction model for health care services. Starting
from the argument that health care services should demonstrate service-dominant rather …

Background Off-label prescribing may lead to adverse drug events. Little is known about its
prevalence and determinants resulting from challenges in documenting treatment indication …

Comparative‐effectiveness research (CER) aims to produce actionable evidence regarding
the effectiveness and safety of medical products and interventions as they are used outside …

OBJECTIVE To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among …